|
1.American Nuclear Society. Nuclear analysis and design of concrete radiation shielding for nuclear power plants. La Grange Park, IL: American National Standards Institute, American Nuclear Society; ANSI/ANS-6.4.2-2006; 2006. 2.Cristy M and Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. Oak Ridge, TN: Oak Ridge National Laboratory; Report ORNL/TM-8381/V1-V7; 1987. 3.D’ Arceuil HE. Technetium-99m tetrofosmin: use for myocardial perfusion imaging in the detection of coronary artery disease. Reports in Medical Imaging 3:1-10; 2010. 4.de Carvalho AB Jr, Stabin MG, Siegel JA, Hunt J. Comparison of point, line and volume dose calculations for exposure to nuclear medicine therapy patients. Health Phys 100:185-190; 2011. 5.GE Healthcare, Medi-Physics, Inc. Myoview package insert. (Amersham—US) Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc.; Recommendation 4; 1996. 6.Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. JAMA 283:2272-2274; 2000. 7.Grove Software Inc. MicroShield user’s manual, version 8.02. Lynchburg, VA: Grove Software Inc.; 2009. 8.Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, Graham D, Hinge D, Davidson J, Lahiri A. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 34:30-38; 1993. 9.International Commission on Radiological Protection. Limits for intakes of radionuclides by Workers. Oxford: Pergamon Press; ICRP Publication 30; 1979. 10.International Commission on Radiological Protection. Data for use in protection against external radiation. Oxford: Pergamon Press; ICRP Publication 51; 1987. 11.International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon Press; ICRP Publication 53; 1987. 12.International Commission on Radiological Protection. 1990 recommendations of the International Commission on Radiological Protection. Oxford: Pergamon Press; ICRP Publication 60; 1991. 13.International Commission on Radiological Protection. Age-dependent doses to members of the public from intake of radionuclides - part 4 inhalation dose coefficients. Oxford: Pergamon Press; ICRP Publication 71; 1995. 14.International Commission on Radiological Protection. Conversion coefficients for use in radiological protection against external radiation. Oxford: Pergamon Press; ICRP Publication 74; 1996. 15.International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. Oxford: Pergamon Press; ICRP Publication 94; 2004. 16.International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals – addendum 3 to ICRP Publication 53. Oxford: Pergamon Press; ICRP Publication 106; 2008. 17.International Commission on Radiological Protection. Adult reference computational phantoms. Oxford: Pergamon Press; ICRP Publication 110; 2009. 18.Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, Chiu KW, Edwards B, Gill HK, McPartlin M, Nagle KR, Latham IA, Pickett RD, Storey AR, Webbon PM. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 34:222-227; 1993. 19.Metting NF. Ionizing radiation dose ranges (sievert) chart. Low Dose Radiation Research Program, Office of Science, U.S. Department of Energy; 2010. http://lowdose.energy.gov/pdf/DoseRanges.pdf 20.National Council on Radiation Protection and Measurements. Precautions in the management of patients who have received therapeutic amounts of radionuclides. Bethesda, MD: NCRP; Report No.37; 1970. 21.Pelowitz DB (Eds). MCNPX user’s manual, version 2.7.0. Los Alamos, NM: Los Alamos National Laboratory; LA-CP-11-00438; 2011. 22.Siegel E. The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, M. D. (1895-1955) and his celebrated patient. Cancer Biother. Radiopharm. 14:71-79; 1999. 23.Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose from radioactive patients: the line-source versus point-source model. J Nucl Med 43:1241-1244; 2002. 24.Smith DS and Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Phys 102:271-291; 2012. 25.Snyder WS, Ford MR, Warner GG, Fisher HL Jr. Estimates of absorbed fractions for monoenergetic photon source uniformly distributed in various organs of a heterogeneous phantom. Medical Internal Radiation Dose Committee (MIRD) Pamphlet No.5, Supplement No.3. J Nucl Med 10:5-52; 1969. 26.Snyder WS, Ford MR, Warner GG, Watson SB. “S,” absorbed dose per unit cumulated activity for selected radionuclides and organs. Medical Internal Radiation Dose Committee (MIRD) Pamphlet No.11. New York, NY: The Society of Nuclear Medicine; 1975. 27.Snyder WS, Ford MR, Warner GG. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. Medical Internal Radiation Dose Committee (MIRD) Pamphlet No.5, Revised. New York, NY: The Society of Nuclear Medicine; 1978. 28.The Society of Nuclear Medicine and Molecular Imaging PET Center of Excellence and the Center of Molecular Imaging Innovation and Translation. [18F]fluorodeoxyglucose, 18F-FDG or FDG. Reston, VA: The Society of Nuclear Medicine and Molecular Imaging; 2012. http://interactive.snm.org/docs/PET_PROS/FDG_K_Zukotynski.pdf 29.Sparks RB, Siegel JA, Wahl RL. The need for better methods to determine release criteria for patients administered radioactive material. Health Phys 75:385-388; 1998. 30.Stabin MG. Radiation protection and dosimetry: an introduction to health physics. New York: Springer; 2007. 31.Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023-1027; 2005. 32.Stabin MG, Watson EE, Marcus CS, Salk RD. Radiation dosimetry for the adult female and fetus from Iodine-131 administration in hyperthyroidism. J Nucl Med 32:808-813; 1991. 33.Stewart BW and Wild CP (Eds). World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014. 34.The Radiation Dose Assessment Resource, RADAR. http://www.doseinfo-radar.com/ 2013. 35.U.S. Nuclear Regulatory Commission. Release of patients administered radioactive materials. Washington, DC: U.S. Government Printing Office; Regulatory Guide 8.39; 1997. 36.Willegaignon J, Guimarães MIC, Stabin MG, Sapienza MT, Malvestini LF, Marone MMS, Sordi GMAA. Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models. Health Phys 93:678-688; 2007. 37.Xu XG and Eckerman KF. Handbook of Anatomical Models for Radiation Dosimetry. London: Taylor & Francis; 2009. 38.Yi Y, Stabin MG, McKaskle MH, Shone MD, Johnson AB. Comparison of measured and calculated dose rates near nuclear medicine patients. Health Phys 105:187-191; 2013. 39.Zankl M, Veit R, Williams G, Schneider K, Fendel H, Petoussi N, Drexler G. The construction of computer tomographic phantoms and their application in radiology and radiation protection. Radiat Environ Biophys 27:153-164; 1988. 40.國家衛生研究院. 2005-2008國人身高、體重、身體質量指數狀況 http://nahsit.nhri.org.tw/node/14/ 2010. |